Evidence map›Paper›PMID 20189877›Full record

ReviewTrends in parasitology2010

Production of recombinant proteins from protozoan parasites.

José A Fernández-Robledo, Gerardo R Vasta

Abstract readReview
In one paragraph

Review in Trends in parasitology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Insights into Peptidyl-ProlylPathogens (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Article
  5. Functional Comparison of Blood-StageFrontiers in immunology · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

José A Fernández-RobledoDepartment of Microbiology and Immunology, University of Maryland School of Medicine, IMET, 701 E. Pratt Street, Suite 236, Baltimore, MD 21202-3101, USA. JFernandez-Robledo@som.umaryland.edu <JFernandez-Robledo@som.umaryland.edu>
Gerardo R Vasta
University of Maryland, Baltimore · US

Funding

A Heterologous Expression System for Apicomplexa GenesR21AI076797 · NIAID · UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE · PI FERNANDEZ-ROBLEDO, JOSE A · 2009 to 2010
$356k
NIAID NIH HHS 1R21AI076797-01A2NIAID NIH HHS R21 AI076797
6 · The paper itself

Abstract

Although the past decade has witnessed sequencing from an increasing number of parasites, modern high-throughput DNA sequencing technologies have the potential to generate complete genome sequences at even higher rates. Along with the discovery of genes that might constitute potential targets for chemotherapy or vaccination, the need for novel protein expression platforms has become a pressing matter. In addition to reviewing the advantages and limitations of the currently available and emerging expression systems, we discuss novel approaches that could overcome current limitations, including the 'pseudoparasite' concept, an expression platform in which the choice of the surrogate organism is based on its phylogenetic affinity to the target parasite, while taking advantage of the whole engineered organism as a vaccination adjuvant.

Indexed as

Cell-Free SystemEukaryotaGene ExpressionProkaryotic CellsProtozoan ProteinsProtozoan VaccinesRecombinant ProteinsProtozoan ProteinsProtozoan VaccinesRecombinant Proteins

Identifiers

PMID20189877
PMCPMC2862126
OpenAlexW2010567241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.